Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2026 09:09 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

CHMP under (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® pill to reduce excess body weight
April 09, 2026 08:28 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU